Inamrinone
- Atc Codes:C01CE
- CAS Codes:60719-84-8
- PHARMGKB ID:60719-84-8
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Inhibits
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
North America
USA: Amrinone.
Drug combinations
Chemistry
Inamrinone: C~10~H~9~N~3~O. Mw: 187.20. [3,4′-Bipyridin]-6(1H)-one, 5-amino-. CAS-60719-84-8 (1999).
Pharmacologic Category
Cardiac Drugs; Cardiotonic Agents; Phosphodiesterase Enzyme Inhibitor. (ATC-Code: C01CE).
Mechanism of action
Inhibits myocardial cyclic adenosine monophosphate (cAMP) phosphodiesterase activity and increases cellular levels of cAMP resulting in positive inotropic effect and increased cardiac output. Systemic and pulmonary vasodilator effects resulting in pre- and afterload reduction. Slightly increases atrioventricular conduction.
Therapeutic use
Short-term management of congestive heart failure.
Pregnancy and lactiation implications
Caution advised if used during pregnancy or in nursing women.
Unlabeled use
Contraindications
Hypersensitivity to inamrinone, any component of the formulation, or bisulfites (contains sodium metabisulfite). Severe aortic or pulmonic valvular disease.
Warnings and precautions
Risk of arrhythmias (might persist even after discontinuation of therapy, especially in renal dysfunction). Might increase ventricular response rate. Hepatic effects might occur. Hypotension possible and might be prolonged, especially in renal dysfunction. Can cause thrombocytopenia (due to decreased platelet survival time). Possible electrolyte imbalance, especially hypokalemia or hypomagnesemia. May aggravate idiopathic hypertrophic subaortic stenosis/hypertrophic obstructive cardiomyopathy. Not recommended in acute myocardial infarction treatment. Long-term therapy treatment of congestive heart failure not recommended. Some formulations contain sulfites. Use with caution in hypertrophic subaortic stenosis since drug may aggravate outflow tract obstruction.